The Board of Scancell Holdings plc, (PLUS:SCLP), the developer of therapeutic cancer vaccines, is pleased to announce that it intends to apply for the Company’s Ordinary Shares to be admitted to trading on AIM and, immediately prior to the Admission to AIM, it intends to withdraw the Company’s Ordinary Shares from trading on PLUS.
During 2010, the Company has raised £2.54 million, before expenses, to fund its foreseeable working capital requirements. The Directors believe that the existing funds held by or available to the Group together with future anticipated revenues will be sufficient to allow completion of the Phase I/IIa clinical trial of SCIB1, its lead melanoma therapeutic vaccine.
The Ordinary Shares of the Company were originally admitted to trading on PLUS in September 2008. However, now that the Company has further strengthened its financial position and progressed the development of SCIB1, the Directors believe that it would be in the best interests of the Company and its shareholders for the Ordinary Shares to be admitted to trading on the AIM market of the London Stock Exchange.
The Directors believe that this represents a natural transition for the Company and that the potential benefits of an AIM listing will include an increased public profile for the Company.
Under the AIM Rules, prior to Admission, the Company is required to publish an admission document. The Company is therefore sending an admission document to Shareholders to inform them that the Ordinary Shares of the Company will be withdrawn from trading on PLUS from the close of business on 29 July 2010 and that the Ordinary Shares of the Company are expected to be admitted to trading on AIM at 8.00 a.m. on 30 July 2010.
The Directors of the issuer accept responsibility for this announcement.
For further information contact:
Professor Lindy Durrant, (CEO) - Scancell Holdings Plc:
John Bick/Kirsty Corcoran - Hansard Communications
Ross Andrews/Tom Rowley - Zeus Capital
Executive chairman John Chiplin said new CEO Dr Cliff Holloway's extensive experience and accomplishments speak volumes
Tue, 10 Oct 2017 08:24:00
“We are continuing to explore a number of funding options to ensure that we have the resources to progress these programmes through their next phase”
Wed, 13 Sep 2017 06:21:00
Chief scientific officer Lindy Durrant presented two posters at the International Cancer Immunotherapy conference in Germany on Friday
Mon, 11 Sep 2017 09:25:00